Status
Conditions
Treatments
About
The purpose of this research is to assess mucosal immune function responses in the gastrointestinal (GI) tract to twice-daily yogurt consumption. Previous research has shown that dairy yogurt intake can benefit gastrointestinal health. The current study will determine whether a dietary intervention with dairy yogurt will improve mucosal immunity and the gut microbiome.
Full description
The gastrointestinal (GI) tract has the difficult task of absorbing nutrients while excluding microorganisms and non-nutritive foreign agents. The GI tract is protected by components of GI mucosal immunity, such as the mucin layer, anti-microbial peptides, secretory IgA (sIgA), and more, which collectively maintain gut homeostasis. When mucosal immunity fails, the result can be gastrointestinal infection, allergic inflammation, or inflammatory bowel disease. Mechanistic knowledge from in vitro studies suggests that sIgA increases in response to lactic acid bacteria and mucin-2 expression increases in response to milk peptides in yogurt. Yogurt consumption may also reduce constipation and increase the production of short-chain fatty acids (SCFAs). SCFAs promote the health of intestinal cells by acting as an energy source, influencing gene expression, and exerting anti-inflammatory effects. When SCFAs increase, fecal pH decreases.
This research will expand the limited existing literature on how GI mucosal immunity changes in response to yogurt consumption, the time frame over which effects occur and how long the effects persist after yogurt is discontinued. Participants will undergo a two-week baseline period without yogurt intake, followed by a three-week intervention of two daily 6-oz servings of dairy yogurt, and a follow-up period with no yogurt consumption. Stool samples will be collected at the end of the 2-week baseline period, after 1, 2, and 3 weeks of intervention, and at the end of the 2 weeks post-intervention period for measurement of fecal sIgA, fecal mucin-2 mRNA, fecal pH, and fecal SCFAs, and analysis of the fecal microbiome. 24-hour dietary recalls will be collected with the Automated Self-Administered Dietary Assessment Tool (ASA24) during the baseline and intervention phases of the trial.
Specific knowledge will be produced regarding the effect of regular yogurt consumption on sIgA levels, mucin-2 gene expression and fecal pH in older adults (age 50 - 75 years). The study will also produce knowledge on the intervention length needed for maximal response in these outcome measures and how long these responses persist when the yogurt intervention is discontinued. The outcomes of this study will 1) provide preliminary data to inform design of future, larger studies on how dairy yogurt or similar cultured products influence GI mucosal immune function, and 2) contribute to growing knowledge on the potential health benefits of consuming fermented, particularly yogurt.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
BMI less than 18.5 or greater than 39.9
Consumption of fermented foods or probiotics in the past two weeks
Unwillingness to abstain from non-study fermented foods and probiotics during the trial
Allergy to cow milk
Lactose intolerance
Any dietary restriction limiting or prohibiting consumption of lightly sweetened, vanilla flavored, whole milk yogurt
Uncomfortable with or unwilling to complete stool sample collections
Current participation in another research study
If female,
Having fewer than 3 bowel movements per week
Unmanaged hypertension, defined as blood pressure greater than or equal to 140/90 mmHg
Current diagnosis of:
Current use for 2 weeks or longer of:
Use of sulfonamides or antibiotics in the past 3 months
Use of laxatives in the past 2 weeks
Currently undergoing cancer treatment with radiation or drugs
History of gastrointestinal surgery that would impact study outcomes, such as gastric bypass, intestinal resection, surgeries of the liver or pancreas, or removal of part or all of any organ of the GI tract
Having within the past 2 weeks:
Having within the past 3 months:
Having within the past 1 month:
Primary purpose
Allocation
Interventional model
Masking
32 participants in 1 patient group
Loading...
Central trial contact
Danielle G Lemay, PhD; Bess L Caswell, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal